{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:12Z","timestamp":1787841312334,"version":"build-2784847793"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/Background:<\/jats:title>\n                    <jats:p>Baseline neutrophil\/lymphocyte ratio (NLR), a surrogate marker for systemic inflammation and immunosuppression, is a well-studied prognostic marker in non-small cell lung cancer (NSCLC). This study tests if interim NLR is prognostic in NSCLC patients in remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This single-center, retrospective cohort study analyzed 131 NSCLC patients treated from 2010 to 2015 who achieved complete remission. NLR was calculated at baseline and from the first available blood sample during remission. Kaplan\u2013Meier estimates of overall survival (OS) and time to recurrence were compared using the log-rank test for trend. Multivariable analysis was conducted using the Cox proportional hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 131 cases, 63 had subsequently recurred at the last follow-up. The mean age was 64 \u00b1 10 years. Patients with stage I (35%), II (24%), and III (41%) were included. Histology were adenocarcinoma (60%), squamous cell (33%), and unspecified (7%). The majority of patients were smokers. For the univariate analysis interim NLR was binned into tertiles, NLR &lt; 2, 2\u20134.08, and &gt; 4.08. Of those with an interim NLR &gt; 4.08, prognosis and recurrence risk were higher. In the multivariable analysis, remission NLR was strongly prognostic for OS (\n                      <jats:italic toggle=\"yes\">p &lt;<\/jats:italic>\n                      .001) as did patient\u2019s age (\n                      <jats:italic toggle=\"yes\">p =<\/jats:italic>\n                      .002), but not stage, race, sex, and baseline NLR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study found that interim NLR, obtained in remission, was strongly prognostic for OS and recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T03:07:18Z","timestamp":1632107238000},"page":"158-161","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Predicting if Lung Cancer Will Relapse\u2013The Role of Neutrophil\/Lymphocyte Ratio"],"prefix":"10.4103","volume":"16","author":[{"given":"Abigail","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Bentzen","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Rout","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"R1-20241211","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-3-319-40389-2_3","article-title":"Lung cancer staging and prognosis","volume":"170","author":"Woodard","year":"2016","journal-title":"Cancer Treat Res"},{"key":"R2-20241211","first-page":"84","article-title":"Prognostic factors in non-small cell lung cancer (NSCLC). Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1359","author":"Holgersson","year":"2017","journal-title":"Uppsala"},{"key":"R3-20241211","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to- lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"R4-20241211","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1634\/theoncologist.2016-0443","article-title":"Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy","volume":"22","author":"Scilla","year":"2017","journal-title":"Oncologist"},{"key":"R5-20241211","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13019-018-0763-0","article-title":"Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer","volume":"13","author":"Mizuguchi","year":"2018","journal-title":"J Cardiothorac Surg"},{"key":"R6-20241211","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to- lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"R7-20241211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"R8-20241211","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2019.01.032","article-title":"Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy","volume":"134","author":"Sebastian","year":"2019","journal-title":"Radiother Oncol"},{"issue":"6917","key":"R9-20241211","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"21","key":"R11-20241211","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.7150\/jca.30478","article-title":"The kinetic changes of systemic inflammatory factors during bevacizumab treatment and its prognostic role in advanced non-small cell lung cancer patients","volume":"10","author":"Li","year":"2019","journal-title":"J Cancer"},{"issue":"15_suppl","key":"R12-20241211","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e21020","article-title":"Association of baseline and longitudinal low neutrophil-lymphocyte ratio (NLR) and high lymphocyte counts (LCs) with progression- free survival (PFS) and overall survival (OS) in real world advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with nivolumab (nivo) or pembrolizumab (pembro)","volume":"36","author":"Labomascus","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"R13-20241211","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3747\/co.23.3191","article-title":"Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy","volume":"23","author":"Valdes","year":"2016","journal-title":"Curr Oncol"},{"issue":"1","key":"R14-20241211","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12029-020-00378-z","article-title":"Differences in baseline characteristics and white blood cell ratios between racial groups in patients with pancreatic adenocarcinoma","volume":"52","author":"Ueberroth","year":"2021","journal-title":"J Gastrointest Cancer"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387621000856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387621000856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2021.08.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:09Z","timestamp":1787838549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2021.08.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2021.08.003","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"assertion":[{"value":"2021-04-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}